David H. Bergstrom
Chief Executive Officer chez Bridge Therapeutics, Inc.
Profil
David H.
Bergstrom is currently the Chief Executive Officer & Director at Bridge Therapeutics, Inc. He previously worked as the Director-Pharmaceutical & Analytical Sciences at Hoechst Marion Roussel, Inc. from 1996 to 1998, and as the Director-Pharmaceutical & Analytical Development at Hoechst-Roussel Pharmaceuticals, Inc. from 1990 to 1996.
From 1999 to 2006, he was the SVP & General Manager-Pharmaceutical Development at Cardinal Health, Inc. He also worked as the VP-Pharmaceutical & Chemical Development at Guilford Pharmaceuticals, Inc. from 1998 to 1999.
He held the position of Chief Operating Officer & Senior Vice President at NovaDel Pharma, Inc. from 2006 to 2012, and as the Chief Operating Officer & Executive Vice President at Eurofins Advantar Laboratories, Inc. He has a doctorate degree from the University of Utah, a graduate degree from the University of Michigan, and an undergraduate degree from Ferris State University (Michigan).
Postes actifs de David H. Bergstrom
| Sociétés | Poste | Début |
|---|---|---|
Bridge Therapeutics, Inc.
 Bridge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bridge Therapeutics, Inc. is a pharmaceutical company. The firm specializes in chronic pain and opioid addiction. The company was founded by Greg Sullivan and is headquartered in Birmingham, AL. | Chief Executive Officer | 01/01/2018 |
Anciens postes connus de David H. Bergstrom
| Sociétés | Poste | Fin |
|---|---|---|
| NOVADEL PHARMA INC | Chief Operating Officer | 31/01/2012 |
| CARDINAL HEALTH, INC. | Chief Tech/Sci/R&D Officer | 01/11/2006 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Chief Tech/Sci/R&D Officer | 01/01/1999 |
| Hoechst Marion Roussel, Inc. | Corporate Officer/Principal | 01/01/1998 |
| Hoechst-Roussel Pharmaceuticals, Inc. | Corporate Officer/Principal | 01/01/1996 |
Formation de David H. Bergstrom
| University of Utah | Doctorate Degree |
| Ferris State University (Michigan) | Undergraduate Degree |
| University of Michigan | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CARDINAL HEALTH, INC. | Distribution Services |
| Entreprise privées | 7 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
Antares Pharma, Inc.
 Antares Pharma, Inc. Pharmaceuticals: MajorHealth Technology Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. Its products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ. | Health Technology |
NovaDel Pharma, Inc.
 NovaDel Pharma, Inc. Pharmaceuticals: MajorHealth Technology NovaDel Pharma, Inc. engages in developing oral spray formulations for different types of drugs. It develops oral spray and pharmaceutical products for angina pectoris, insomia, migraine headaches, and disorders of the central nervous system. The company was founded in 1982 and is headquartered in Bridgewater, NJ. | Health Technology |
| Hoechst Marion Roussel, Inc. | |
| Hoechst-Roussel Pharmaceuticals, Inc. | |
Eurofins Advantar Laboratories, Inc.
 Eurofins Advantar Laboratories, Inc. BiotechnologyHealth Technology Eurofins Advantar Laboratories, Inc. specializes in analytical development and formulation services for large molecule and small molecule programs, medical devices, and novel combination products. Its services include biophysical characterization, bimolecular and small molecules, FTE programs, data review support, regulatory and CMC consulting, litigation support and expert testimony, PAI audit and FDA response support. The company was founded by David F. Hale, John Alaimo, Richard A. Kenley, and Edward Foster in 2008 and is headquartered in San Diego, CA. | Health Technology |
Bridge Therapeutics, Inc.
Bridge Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bridge Therapeutics, Inc. is a pharmaceutical company. The firm specializes in chronic pain and opioid addiction. The company was founded by Greg Sullivan and is headquartered in Birmingham, AL. | Health Technology |
